Table 1 Patient baseline characteristics
Characteristic | Pomalidomide plus dexamethasone (NÂ =Â 36) |
|---|---|
Age | |
 Median (range), years | 64.5 (43–78) |
 >65 years, n (%) | 17 (47.2) |
 >75 years, n (%) | 4 (11.1) |
Sex, n (%) | |
 Male | 16 (44.4) |
 Female | 20 (55.6) |
Time from first diagnosis, median (range), years | 4.7 (0.6–21.1) |
ECOG performance status, n (%) | |
 0–1 | 33 (91.7) |
 2 | 3 (8.3) |
Durie–Salmon stage, n (%) | |
 I | 7 (19.4) |
 II | 16 (44.4) |
 III | 13 (36.1) |
β2-microglobulin level, n (%) | |
 <3.5 mg/L | 24 (66.7) |
 3.5–<5.5 mg/L | 10 (27.8) |
 ≥5.5 mg/L | 2 (5.6) |
Bone lesions, n (%) | 22 (61.1) |
Extramedullary plasmacytoma, n (%) | 5 (13.9) |
Creatinine clearance, n (%) | |
 <30 mL/min | 0 |
 30–<45 mL/min | 0 |
 45–<60 mL/min | 8 (22.2) |
 60–<80 mL/min | 13 (36.1) |
 ≥80 mL/min | 15 (41.7) |
Prior antimyeloma therapies, median (range) | 6.5 (2–15) |
Prior stem cell transplant, n (%) | 19 (52.8) |
Prior therapies, n (%) | |
 Lenalidomide | 36 (100.0) |
 Bortezomib | 36 (100.0) |
 Thalidomide | 12 (33.3) |
 Dexamethasone | 35 (97.2) |
 Melphalan | 31 (86.1) |
Last prior therapy, n (%) | |
 Lenalidomide | 21 (58.3) |
 Bortezomib | 15 (41.7) |
Refractory to prior therapies, n (%) | |
 Lenalidomide | 35 (97.2) |
 Bortezomib | 21 (58.3) |
 Both lenalidomide and bortezomib | 21 (58.3) |